Replies to post #18665 on Marker Therapeutics Inc (MRKR)

[blackbandit]

The ones that are done in order to uplist are completely different than doing one to regain or maintain a nasdaq listing. TPIV is most likely doing one now because of all the trial news they plan to provide in the upcoming weeks, months. As long as they provide positive results, then they are far better off on the nasdaq than OTC. If they provide nothing, then you are right, they'll drift back down. But with 4 trials that should all be under way within a few months, this appears to be the start of the TPIV story. All IMHO.

[billnew5]

Up over 20% from pre-split price. Pulling back on low volume. Not necessarily bad. When up list happens with participation of funds and institutional investors, could see nice increase

[Phantom Lord]

Maybe you should do your research as bandit has clearly done his. Your 90% is just a random number you threw out to make an invalid point. If they are done to avoid de-listing then yes, generally a bad sign. If they are done to uplist the story is completely different. Obviously interest needs to be there in order to keep the price up and luckily for us we consolidated in a small range before the split so no reason do drop below that. Other companies reverse split right after large runs up which inevitable need to cool off. Not because they split their stock to uplist but because the prior run was exhausted. Each case is different and you cant lump them all together. For every example of one that went bad I can give you one that went well. Or at the very least give you the actual reason for why they drifted lower after the split. Every drop has it's reason and most people choose to look at the split as the cause when if they dug a little deeper they would find the real reason for the dip. My advice to you: dig deeper. You clearly do your research but maybe do a little more before you start telling other people to do theirs.